Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Google Secures Pentagon AI Deal for Classified Projects 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
NEWARK, Calif., May 02, 2017 -- Depomed, Inc. (NASDAQ:DEPO) today announced that it will release first quarter fiscal year 2017 financial results on Tuesday, May 9, 2017, after the close of markets. The Company will host a conference call beginning at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its results.
Participants can access the call by dialing (844) 839-0046 (United States) or (857) 270-6032 (International) referencing Conference ID 10761035. The conference call will also be available via a live webcast on the Investor Relations section of Depomed's website at http://www.depomed.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.
About Depomed
Depomed is a leading specialty pharmaceutical company focused on enhancing the lives of the patients, families, physicians, providers and payors we serve through commercializing innovative products for pain and neurology related disorders. Depomed markets six medicines with areas of focus that include mild to severe acute pain, moderate to severe chronic pain, neuropathic pain, migraine and breakthrough cancer pain. Depomed is headquartered in Newark, California. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACT: Christopher Keenan VP, Investor Relations and Corporate Communications 510-744-8000 [email protected]
